Navigation Links
Draper Nanotechnology Could Fight Influenza, Other Viruses
Date:1/7/2014

Cambridge, MA (PRWEB) January 07, 2014

Newly emerging flu viruses could soon be countered by a treatment that Draper Laboratory is developing that “traps” viruses before they can infect host cells.

Further into the future, patients suffering from any type of virus could be cured with DRACO, a drug also under development at Draper that is designed to rapidly recognize and eliminate cells infected by virtually any virus.

Both methods could help safeguard against bioterrorist attacks and naturally occurring pandemics in a manner that is unlikely to lead to treatment-resistant strains. Initial testing on the treatments, which each use tiny, non-toxic particles that can be injected, inhaled, or eaten, has shown them to be effective and safe against a multitude of strains of disease.

Nanotraps, which could be taken at the first sign of infection or exposure, is likely the first of the products ready for use, and is expected to begin clinical trials in two to five years, according to Jim Comolli, who leads the research on the effort at Draper.

Nanotraps, developed by a team of researchers from Draper, MIT, the University of Massachusetts Medical School, and the University of Santa Barbara, are nanoparticles that act as viral “traps” using specific molecules found naturally within the human body. A paper published in the March issue of Journal of Biological Chemistry detailed their findings.

The nanotraps look like the surface of a cell, with numerous carbohydrate molecules attached that closely resemble those targeted by flu viruses in the human respiratory system. These molecules, initially characterized in the Sasisekharan Lab at MIT, act as bait for the flu virus, which bind to the nanotrap instead of a host cell and are cleared away with mucus, preventing infection, Comolli said.

The research team has demonstrated in the laboratory that the nanotraps effectively countered multiple influenza strains able to infect humans and went on to show nanotraps protected mice infected with the flu. They have also developed additional particles geared toward other types of respiratory viruses.

Nanotraps, unlike most vaccines, are not strain specific and are designed to be effective against newly emerging strains of human-adapted influenza virus. Since nanotraps mimic a fundamental step in the viral life cycle – the binding of the virus to a host cell’s receptor – nanotraps may offer an opportunity to treat devastating infectious diseases without causing the development of treatment resistance, Comolli said.

The nanotrap molecule is composed mainly of compounds found naturally in the human body so it is likely to be safe as an inhalant, topical solution, or intravenous treatment and inexpensive to manufacture. With further development, nanotraps have the potential to treat a large range of infectious diseases because the attached carbohydrates can be tuned for other viruses such as HIV, Respiratory Syncytial Virus (RSV), and Herpes Simplex Virus (HSV), as well as bacteria and toxins.

The work was originally funded by the Defense Advanced Research Projects Agency (DARPA) to address emerging pandemics or bioweapons targeting US troops; Draper is continuing the research with the intent of applying it more broadly to the civilian community.

While nanotraps could be customized to treat a variety of viruses, another project underway at Draper, DRACO could do so with a single approach. DRACO is a unique therapeutic drug that should be effective against a very broad spectrum of viruses, just as existing antibiotics are effective against a broad range of bacterial infections. DRACO could be ready for human clinical trials in five to 10 years, according to Todd Rider, who leads the research at Draper.

DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is designed to detect cells that have been virally infected and then eradicate only the infected cells, rapidly ending the infection. DRACO has proven effective in vivo against influenza and three hemorrhagic fever viruses, and in vitro against 15 different viruses – including common cold viruses, the H1N1 influenza strain, adenoviruses, a mouse polio virus, dengue fever, and stomach viruses, among others. It has also been tested and proven safe in both mice and 11 different human and animal cell types representing organs like the heart, lungs, liver, and kidney, among others.

DRACO is designed to be attracted to a specific type of RNA exclusive to viral infections – long double-stranded RNA, or dsRNA. Detecting this dsRNA in a human or animal cell indicates that that host cell has been taken over by a virus and is now in the process of creating more viruses. DRACO enters cells and attaches itself to any dsRNA. Once two or more DRACOs attach to the dsRNA, they interact with one another and activate a natural self-destruct switch inside the infected cell, terminating the infected cell and the virus that it was helping to reproduce.

DRACO is designed to be both broad-spectrum and nontoxic to humans – overcoming existing issues with current anti-viral treatments. Because DRACO is so broad-spectrum and acts so rapidly, there is little opportunity for the virus to evolve defenses against this treatment, Rider said.

Rider is expanding his DRACO research and testing more strains of various viruses in cells and animals.

DRACO has been funded by grant AI057159 from the National Institute of Allergy and Infectious Diseases and the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, with other funding coming from DARPA, the Defense Threat Reduction Agency, and the office of the Director of Defense Research and Engineering.

Draper Laboratory

Draper Laboratory, which celebrates 80 years of service to the nation in 2013, is a not-for-profit, engineering research and development organization dedicated to solving critical national problems in national security, space systems, biomedical systems, and energy. Core capabilities include guidance, navigation and control, miniature low power systems, highly reliable complex systems, information and decision systems, autonomous systems, biomedical and chemical systems, and secure networks and communications.

http://www.draper.com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11445483.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Draper Mobile Technology Could Aid War on Obesity
2. Health Officials Could Identify & Act on Crises Earlier With New Draper Biosurveillance Tool
3. Draper/MIT Space Suits Could Enable Asteroid Exploration, Satellite Repairs
4. Draper Device Could Help Pave Way Towards “Kidney-On-A-Chip” Development
5. Nanotechnology experts to gather in Singapore for 3rd Nano Today Conference
6. ‘Wonder of Nanotechnology’ Details Research Enabling Nanoscale Optoelectronic Devices
7. “Outlook” with “Ben Kingsley” Features Programming Discussing the Role of Nanotechnology in Medicine
8. Will Safety Concerns Slow Nanotechnology Drug Delivery Market Growth? Forecasts Predict 84.79% Growth in US, 73.97% Globally through 2016
9. Regenerative Medicine Company, Eqalix, Announces Grant from Nanotechnology Institute in Philadelphia, Pennsylvania
10. Lockheed Martin and Nanyang Technological University to collaborate on nanotechnology
11. Notre Dame study explores the potential benefits and threats of nanotechnology research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... -- The immunohistochemistry (IHC) market is projected to ... 7.3% during the forecast period of 2016 to 2021 dominated by ... for the largest share of immunohistochemistry (IHC) market, by end user. ... , , ... spread across 225 pages, profiling 10 companies and supported with 181 ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
Breaking Biology Technology:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):